Research

*December 2024* Learn about the latest research on how non-small cell lung cancer can transform into small cell lung cancer and how that can impact treatment options from Jacob Berchuck, MD, Board-Certified Medical Oncologist at Emory University in this Expert Speaker video. Watch here.

*June 2025* Highlights Case series of tepotinib plus EGFR-TKIs in patients with EGFR-mutant, MET-altered NSCLC. Clinical benefit (23/25) and favorable safety shown in these heavily pretreated patients. These combinations provide a potential chemotherapy-sparing, oral therapy option. Clinical Practice Points No targeted treatments are currently approved for patients with EGFR-mutant non–small-cell lung…

*March 2025* Fort Lee, NJ, March 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a  new publication from…

*March 2025* Cell-based immunotherapies such as chimeric antigen receptor T cells (CAR-T) have transformed cancer care in recent years, dramatically improving the treatment of blood cancers in particular. But traditional autologous CAR-T therapy has some drawbacks that may limit how many patients it can help. Harvesting, engineering and readministering a…

*March 2025* Hear from experts Dr. Jona Hattangadi-Gluth and Dr. Jonathan Yang about radiation therapy for leptomeningeal cancer. Learn the difference between proton and photon therapy, how treatment plans are developed, and the latest in clinical trials. Watch here.

*March 2025* The FDA has granted orphan drug designation to the investigational radiotherapeutic rhenium (186Re) obisbemeda as a potential therapeutic option for leptomeningeal metastases in patients with lung cancer.1 Rhenium (186Re) obisbemeda is formulated to deliver highly targeted, high-dose radiation directly to central nervous system (CNS) tumors with the goal…

*March 2025* MARIPOSA2 Study: What happens if you are on osimertinib and it stops working? Can you still get amivantamab? Dr. Eric Singhi explains here. MARIPOSA Study: Amivantamab + lazertinib vs osimertinib OS benefit in first-line. Dr. Eric Singhi explains here. Jill Feldman: Presenting COCOON and MARIPOSA together tells a…

*March 2025* What is the next step for patients with EGFR-mutated non-small cell lung cancer (NSCLC) whose disease has progressed on first-line osimertinib (Tagrisso), but who have no identifiable biomarkers to guide second-line therapy? Early results from the phase 2 ORCHARD platform study suggest that the next step could be adding the…